Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force
Authors:
- Holly L. PacentaHPHolly L. Pacenta
- Wendy Allen-RhoadesWAWendy Allen-Rhoades
- David LangenauDLDavid Langenau
- Peter J. HoughtonPHPeter J. Houghton
- Charles KellerCKCharles Keller
- Christine M. HeskeCHChristine M. Heske
- Michael D. DeelMDMichael D. Deel
- Corinne M. LinardicCLCorinne M. Linardic
- Jack F. ShernJSJack F. Shern
- Elizabeth StewartESElizabeth Stewart
- Brian TurpinBTBrian Turpin
- Douglas J. HarrisonDHDouglas J. Harrison
Open Access
- 1 April 2021
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (7) , 1416
Abstract
Rhabdomyosarcoma is the most common soft tissue sarcoma diagnosed in children and adolescents. Patients that are diagnosed with advanced or relapsed disease have exceptionally poor outcomes. The Children’s Oncology Group (COG) convened a rhabdomyosarcoma new agent task force in 2020 to systematically evaluate novel agents for inclusion in phase 2 or phase 3 clinical trials for patients diagnosed with rhabdomyosarcoma, following a similar effort for Ewing sarcoma. The task force was comprised of clinicians and basic scientists who collectively identified new agents for evaluation and prioritization in clinical trial testing. Here, we report the work of the task force including the framework upon which the decisions were rendered and review the top classes of agents that were discussed. Representative agents include poly-ADP-ribose polymerase (PARP) inhibitors in combination with cytotoxic agents, mitogen-activated protein kinase (MEK) inhibitors in combination with type 1 insulin-like growth factor receptor (IGFR1) inhibitors, histone deacetylase (HDAC) inhibitors, and novel cytotoxic agents.Keywords
Funding Information
- NCTN Operations Center (U10CA180886)
- NCTN Statistics & Data Center (U10CA180899)
This publication has 119 references indexed in Scilit:
- Oncogenic NRAS, Required for Pathogenesis of Embryonic Rhabdomyosarcoma, Relies upon the HMGA2–IGF2BP2 PathwayCancer Research, 2013
- A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and LymphomasClinical Cancer Research, 2012
- Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cellsProceedings of the National Academy of Sciences, 2011
- EphrinA/EphA signal facilitates insulin-like growth factor-I–induced myogenic differentiation through suppression of the Ras/extracellular signal–regulated kinase 1/2 cascade in myoblast cell linesMolecular Biology of the Cell, 2011
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasCancer Research, 2011
- Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and CancerCancer Research, 2010
- Eph receptors and ephrins in cancer: bidirectional signalling and beyondNature Reviews Cancer, 2010
- Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology GroupClinical Cancer Research, 2010
- Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing ProgramMolecular Cancer Therapeutics, 2010
- Effects of RAS on the genesis of embryonal rhabdomyosarcomaGenes & Development, 2007